Selected research
Industry Research
Human Immunodeficiency Virus Type-1 Industry Research Report 2026
Market perspective
The global Human Immunodeficiency Virus Type-1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Human Immunodeficiency Virus Type-1 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human Immunodeficiency Virus Type-1 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human Immunodeficiency Virus Type-1 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human Immunodeficiency Virus Type-1 include AstraZeneca, Bayer, Bristol Myers Squibb, Merck & Co. Inc., Novartis, Pfizer, Viatris, GSK and Roche and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Human Immunodeficiency Virus Type-1 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human Immunodeficiency Virus Type-1.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Immunodeficiency Virus Type-1 Market by Company
AstraZeneca
Bayer
Bristol Myers Squibb
Merck & Co. Inc.
Novartis
Pfizer
Viatris
GSK
Roche
Sanofi
Human Immunodeficiency Virus Type-1 Segment by Type
Integrase Inhibitor
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Protease Inhibitors (PIs)
Others
Human Immunodeficiency Virus Type-1 Segment by Application
Retail Pharmacies
Hospital Pharmacies
Human Immunodeficiency Virus Type-1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunodeficiency Virus Type-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Immunodeficiency Virus Type-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunodeficiency Virus Type-1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Immunodeficiency Virus Type-1 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Integrase Inhibitor
- Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Protease Inhibitors (PIs)
- Others
Applications
- Retail Pharmacies
- Hospital Pharmacies
Companies covered
- AstraZeneca
- Bayer
- Bristol Myers Squibb
- Merck & Co. Inc.
- Novartis
- Pfizer
- Viatris
- GSK
- Roche
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Human Immunodeficiency Virus Type-1 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Integrase Inhibitor
- 2.2.3 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
- 2.2.4 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 2.2.5 Protease Inhibitors (PIs)
- 2.2.6 Others
- 2.3 Human Immunodeficiency Virus Type-1 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Retail Pharmacies
- 2.3.3 Hospital Pharmacies
- 2.4 Assumptions and Limitations
3 Human Immunodeficiency Virus Type-1 Breakdown Data by Type
- 3.1 Global Human Immunodeficiency Virus Type-1 Historic Market Size by Type (2021-2026)
- 3.2 Global Human Immunodeficiency Virus Type-1 Forecasted Market Size by Type (2027-2032)
4 Human Immunodeficiency Virus Type-1 Breakdown Data by Application
- 4.1 Global Human Immunodeficiency Virus Type-1 Historic Market Size by Application (2021-2026)
- 4.2 Global Human Immunodeficiency Virus Type-1 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Human Immunodeficiency Virus Type-1 Market Perspective (2021-2032)
- 5.2 Global Human Immunodeficiency Virus Type-1 Growth Trends by Region
- 5.2.1 Global Human Immunodeficiency Virus Type-1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Human Immunodeficiency Virus Type-1 Historic Market Size by Region (2021-2026)
- 5.2.3 Human Immunodeficiency Virus Type-1 Forecasted Market Size by Region (2027-2032)
- 5.3 Human Immunodeficiency Virus Type-1 Market Dynamics
- 5.3.1 Human Immunodeficiency Virus Type-1 Industry Trends
- 5.3.2 Human Immunodeficiency Virus Type-1 Market Drivers
- 5.3.3 Human Immunodeficiency Virus Type-1 Market Challenges
- 5.3.4 Human Immunodeficiency Virus Type-1 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Human Immunodeficiency Virus Type-1 Players by Revenue
- 6.1.1 Global Top Human Immunodeficiency Virus Type-1 Players by Revenue (2021-2026)
- 6.1.2 Global Human Immunodeficiency Virus Type-1 Revenue Market Share by Players (2021-2026)
- 6.2 Global Human Immunodeficiency Virus Type-1 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Human Immunodeficiency Virus Type-1 Head Office and Area Served
- 6.4 Global Human Immunodeficiency Virus Type-1 Players, Product Type & Application
- 6.5 Global Human Immunodeficiency Virus Type-1 Manufacturers Established Date
- 6.6 Global Human Immunodeficiency Virus Type-1 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Human Immunodeficiency Virus Type-1 Market Size (2021-2032)
- 7.2 North America Human Immunodeficiency Virus Type-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Human Immunodeficiency Virus Type-1 Market Size by Country (2021-2026)
- 7.4 North America Human Immunodeficiency Virus Type-1 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Human Immunodeficiency Virus Type-1 Market Size (2021-2032)
- 8.2 Europe Human Immunodeficiency Virus Type-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Human Immunodeficiency Virus Type-1 Market Size by Country (2021-2026)
- 8.4 Europe Human Immunodeficiency Virus Type-1 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size (2021-2032)
- 9.2 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Human Immunodeficiency Virus Type-1 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Human Immunodeficiency Virus Type-1 Market Size (2021-2032)
- 10.2 South America Human Immunodeficiency Virus Type-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Human Immunodeficiency Virus Type-1 Market Size by Country (2021-2026)
- 10.4 South America Human Immunodeficiency Virus Type-1 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Human Immunodeficiency Virus Type-1 Market Size (2021-2032)
- 11.2 Middle East & Africa Human Immunodeficiency Virus Type-1 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Human Immunodeficiency Virus Type-1 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Human Immunodeficiency Virus Type-1 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AstraZeneca
- 12.1.1 AstraZeneca Company Information
- 12.1.2 AstraZeneca Business Overview
- 12.1.3 AstraZeneca Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.1.4 AstraZeneca Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.1.5 AstraZeneca Recent Developments
- 12.2 Bayer
- 12.2.1 Bayer Company Information
- 12.2.2 Bayer Business Overview
- 12.2.3 Bayer Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.2.4 Bayer Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.2.5 Bayer Recent Developments
- 12.3 Bristol Myers Squibb
- 12.3.1 Bristol Myers Squibb Company Information
- 12.3.2 Bristol Myers Squibb Business Overview
- 12.3.3 Bristol Myers Squibb Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.3.4 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.3.5 Bristol Myers Squibb Recent Developments
- 12.4 Merck & Co. Inc.
- 12.4.1 Merck & Co. Inc. Company Information
- 12.4.2 Merck & Co. Inc. Business Overview
- 12.4.3 Merck & Co. Inc. Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.4.4 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.4.5 Merck & Co. Inc. Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.5.4 Novartis Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.6.4 Pfizer Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Viatris
- 12.7.1 Viatris Company Information
- 12.7.2 Viatris Business Overview
- 12.7.3 Viatris Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.7.4 Viatris Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.7.5 Viatris Recent Developments
- 12.8 GSK
- 12.8.1 GSK Company Information
- 12.8.2 GSK Business Overview
- 12.8.3 GSK Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.8.4 GSK Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.8.5 GSK Recent Developments
- 12.9 Roche
- 12.9.1 Roche Company Information
- 12.9.2 Roche Business Overview
- 12.9.3 Roche Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.9.4 Roche Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.9.5 Roche Recent Developments
- 12.10 Sanofi
- 12.10.1 Sanofi Company Information
- 12.10.2 Sanofi Business Overview
- 12.10.3 Sanofi Revenue in Human Immunodeficiency Virus Type-1 Business (2021-2026)
- 12.10.4 Sanofi Human Immunodeficiency Virus Type-1 Product Portfolio
- 12.10.5 Sanofi Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst